Press Releases

20/02/2019 : Theradiag reports annual revenues for 2018 and its year-end cash position

Consolidated 2018 revenues: €8.9 million Continued growth in sales of Lisa Tracker® kits for routine use: 17% Cash position: €3.4 million   Croissy-Beaubourg, February 20, 2019, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a…

Continue Reading20/02/2019 : Theradiag reports annual revenues for 2018 and its year-end cash position

15/01/2019 : THERADIAG reaffirms its leadership position in biotherapy monitoring with a new test being granted the CE mark

Cosentyx®: 12th CE mark for the LISA TRACKER® range Croissy-Beaubourg, January 15, 2019, 6 pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announces that it has…

Continue Reading15/01/2019 : THERADIAG reaffirms its leadership position in biotherapy monitoring with a new test being granted the CE mark

11/12/2018 : Appointment of Bertrand de Castelnau as Chief Executive Officer of Theradiag

Croissy-Beaubourg, December 11, 2018, 6.00pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced the appointment by its Board of Directors of Bertrand de Castelnau as…

Continue Reading11/12/2018 : Appointment of Bertrand de Castelnau as Chief Executive Officer of Theradiag